Limitations of widely used high-risk human papillomavirus laboratory-developed testing in cervical cancer screening

Sonya Naryshkin 1
R Marshall Austin 2

1 Department of Pathology, Mercy Health System, Janesville, WI;
2 Department of Pathology, Magee-Womens Hospital of University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Objective: To increase awareness of the limitations of high-risk human papillomavirus (hrHPV) laboratory-developed testing (LDT) widely used in US cervical cancer screening.

Methods and results: A young woman in her 30s was diagnosed and treated for stage 1B1 cervical squamous cell carcinoma in which HPV 16 DNA was detected using polymerase chain reaction testing. Both 1 month before and 42 months before cervical cancer diagnosis, the patient had highly abnormal cytology findings; however, residual SurePath™ (Becton, Dickson and Company, Franklin Lakes, NJ) vial fluid yielded negative Hybrid Capture 2 (HC2; Qiagen NV, Hilden, Germany) hrHPV LDT results from each of the two specimens. This prompted questions to be asked concerning the performance characteristics of hrHPV LDT. A review of the available data indicates that (1) purification of DNA from SurePath specimens requires complex sample preparation due to formaldehyde crosslinking of proteins and nucleic acids, (2) HC2–SurePath hrHPV testing had not been Food and Drug Administration-approved after multiple premarket approval submissions, (3) detectable hrHPV DNA in the SurePath vial decreases over time, and (4) US laboratories performing HC2–SurePath hrHPV LDT testing are not using a standardized manufacturer-endorsed procedure.

Conclusion: Recently updated cervical screening guidelines in the US recommend against the use of hrHPV LDT in cervical screening, including widely used HC2 testing from the SurePath vial. The manufacturer recently issued a technical bulletin specifically warning that use of SurePath samples with the HC2 hrHPV test may provide false negative results and potentially compromise patient safety. Co-collection using a Food and Drug Administration-approved hrHPV test medium is recommended for HPV testing of patients undergoing cervical screening using SurePath samples.

Keywords: HPV, SurePath, Hybrid Capture 2, LDT, cervical screening

Introduction
Since 2001, adjunctive high-risk human papillomavirus (hrHPV) testing has become increasingly integrated along with cytologic testing as a part of routine US cervical cancer screening, initially as a “preferred” reflex test after atypical cells of undetermined significance liquid-based cytology results and on a more widespread basis after 2003 Food and Drug Administration (FDA) approval for routine cytology and HPV cotesting of women 30 years and older. 1,2 Recently updated cervical screening guidelines from the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society for Clinical Pathology have proposed significantly lengthened screening intervals, particularly for patients with negative hrHPV test results and either negative or equivocally abnormal (atypical cells of undetermined significance)
cytology findings. For women 30 years and older with either hrHPV-negative atypical cells of undetermined significance or “double negative” results, a screening interval of 5 years has for the first time been recommended. The guidelines, however, emphasize that the new extended screening intervals following negative hrHPV test results are based on HPV tests with performance characteristics similar to HPV tests used in the supporting evidence. Since at least one-third of all US hrHPV tests use laboratory-developed test (LDT) methodology, largely exempt from regulatory oversight by the FDA and unlikely to have undergone rigorous evaluation using grade 3+ or grade 2+ cervical intraepithelial neoplasia clinical endpoints in properly designed trials, the guidelines publications specifically recommend against the use of HPV LDTs for cervical cancer screening.

The most common form of hrHPV LDT to date has been Hybrid Capture 2 (HC2; Qiagen NV, Hilden, Germany) performed on residual SurePath™ vial fluid (Becton, Dickinson and Company, Franklin Lakes, NJ). Although HC2 hrHPV testing is FDA-approved from both the Digene® (Qiagen) specimen transport medium tube (Qiagen) and the methanol-based PreservCyt® vial (Hologic, Inc, Bedford, MA), HC2 hrHPV testing from the SurePath vial to date has not been able to obtain FDA approval, despite multiple premarket approval submissions, beginning in 2002. In a 2002 press release, the manufacturer stated: “We remain hopeful that resolution of the FDA’s issues will not significantly alter our prior expectations for introduction in 2003.” Qiagen investigators have acknowledged that purification of DNA from SurePath specimens requires complex sample preparation due to the formaldehyde crosslinking of proteins and nucleic acids. Three additional hrHPV tests have now also gained FDA approval from either the PreservCyt vial or also from proprietary manufacturer’s collection media, but none of these newer FDA-approved hrHPV tests have been approved using the SurePath vial.

Recently, the authors encountered a patient diagnosed with invasive cervical cancer with two prior significantly abnormal Pap tests and two negative hrHPV LDT cotest results. Since virtually all cervical cancers are now thought to be due to persistent carcinogenic hrHPV infections, this case was investigated to better understand the possible causes of negative hrHPV LDT in screened patients developing cervical cancer.

Case report
The patient was a young woman in her 30s, a gravida 3, para 3 cigarette smoker with a long history of abnormal Pap test results and inconsistent follow-up due to medical appointment cancellations which the patient attributed to intermittent lack of insurance coverage. Forty-two months before her diagnosis of cervical cancer, the patient had a SurePath Pap test interpreted as “atypical squamous cells, cannot rule out a high-grade squamous intraepithelial lesion” (Figure 1). Because the patient’s gynecologist had ordered routine cytology and HPV cotesting in a woman 30 years and older, the residual SurePath vial fluid was sent to a regional laboratory facility of a large national commercial laboratory. The hrHPV test result was reported as “not detected.” In that report, an additional comment stated that “patients without hrHPV rarely have cervical cancer.” There was no comment concerning the performance characteristics of this LTD. A cervical biopsy obtained 4 months later reported kiklocytosis and an endocervical curettage as benign. A second SurePath Pap test obtained 19 months later was reported as “high-grade squamous intraepithelial lesion.” The patient failed to return for scheduled colposcopic evaluation. Eighteen months later, the patient presented with irregular painful periods that were getting worse. A third SurePath Pap test was obtained and reported as “high-grade squamous intraepithelial lesion” (Figure 2). The patient’s gynecologist had again ordered routine cytology and hrHPV cotesting in a woman 30 years or older, and therefore the residual SurePath vial fluid was again sent to the regional laboratory that had previously performed hrHPV testing. The hrHPV

Figure 1 Abnormal SurePath Pap test cells interpreted as “atypical squamous cells, cannot rule out a high-grade squamous intraepithelial lesion” (original magnification 400×); residual SurePath vial fluid tested negative using the Hybrid Capture 2 test for high-risk human papillomavirus. Note: Forty-two months later the patient was diagnosed with stage IB1 cervical squamous cell carcinoma.
test, which utilized hybrid capture with signal amplification, was – as before – reported as “not detected.” In this report, however, an additional comment stated that “the analytical performance characteristics of this assay, when used to test SurePath or vaginal specimens, have been determined by (the laboratory).” The patient’s SurePath Pap test slides were reviewed and photographed for documentation.

A cold knife conization was performed 1 month later and the presence of a poorly differentiated squamous cell carcinoma (SCC) measuring $1 \times 1 \times 0.5$ cm and extending to multiple biopsy margins was documented. One month later at an outside cancer referral center, the patient underwent a radical hysterectomy, bilateral pelvic lymph node dissection, bilateral salpingectomy, and left oophorectomy. Final pathologic diagnosis was of a cervical SCC (1.5 cm maximum tumor dimension) invading the upper third of the cervix with no lymphovascular invasion identified, and negative lymph nodes – stage 1B1 (Figure 3). No further therapy was recommended. Twenty-six months later, at last follow-up, the patient was reported as alive and well with no evidence of disease.

Paraffin sections of SCC samples from the patient’s cold knife conization specimen were used for hrHPV testing by polymerase chain reaction methods. HPV in tumor sections was initially tested for using M09/M11 PCR primers, which amplify an approximately 450 base pair conserved region of the L1 gene of HPV. HPV type-specific PCR was also performed by PCR amplification of portions of E6 and E7

Figure 2 Abnormal SurePath Pap test cells interpreted as “high-grade squamous intraepithelial lesion” (original magnification 400×); residual SurePath vial fluid tested negative using the Hybrid Capture 2 test for high risk human papillomavirus.

Note: One month later the patient was diagnosed with stage 1B1 cervical squamous cell carcinoma.

Figure 3 Invasive poorly differentiated cervical squamous carcinoma (original magnification 200×); diagnosed after two negative Hybrid Capture 2 human papillomavirus tests from SurePath vial fluid.

Note: Human papillomavirus 16 DNA was detected in tumor tissue by polymerase chain reaction.
followed by automated DNA sequencing of the amplified products. Using these methods, presence of HPV 16 type-specific E6 was documented along with L1 deletion. Thus, the hrHPV tests from the SurePath vials were true false negative results. Fortunately, in the case of this patient, the false negative results did not affect her course or management.

**Discussion**

Confirmation of the presence of HPV 16 DNA by PCR in this patient’s invasive cervical SCC is consistent with the current understanding that persistent infections with a group of approximately a dozen carcinogenic HPV genotypes cause virtually all cases of cervical cancer worldwide. However, negative HC2 hrHPV test results from residual SurePath vial fluid 42 months and 1 month before tumor diagnosis were unexpected. Since both Pap tests contained highly abnormal cells (atypical squamous cells, cannot rule out a high-grade squamous intraepithelial lesion and high-grade squamous intraepithelial lesion), the discrepancy cannot be attributed to a failure to sample lesional cells. In fact, it has been argued that one advantage of HC2 cotesting is that HC2 may detect hrHPV DNA in patients with occult invasive cervical cancer, even when lesional cells are not sampled.  

In the largest study of HC2 tests collected in FDA-approved specimen transport medium, positive hrHPV HC2 results were reported in 185 of 198 (93.4%) samples collected from patients with simultaneous histopathologic diagnoses of invasive cervical cancer.  

In the same study, similar positive hrHPV HC2 test results were reported in 246 of 264 (93.2%) specimen transport medium tubes collected from patients with simultaneous histopathologic diagnoses of grade 3 cervical intraepithelial neoplasia.  

In contrast, the very limited data from the most widely cited US laboratory self-validation study of HPV testing from the SurePath vial showed positive hrHPV HC2 results for patients with cancer in only 33% (one of three tests) or 50% (one of two patients). Also in contrast to the above cited data, the authors puzzlingly asserted that false negative hrHPV screening test results in patients with invasive cervical cancer are “not surprising.”  

HC2 uses a positive cut point of 1.0 relative light units per positive control, a cut point which corresponds to greater than or equal to 5000 HPV DNA copies per test well, based on a receiver operating characteristic curve analysis versus cervical intraepithelial neoplasia grade 2+, to minimize the detection of lower viral load HPV infections that are mostly benign. Nevertheless, a subset of invasive cervical cancers associated with low viral load have been described, and low viral loads in patients with developing invasive cervical cancer may fall below the detection cut point of FDA-approved hrHPV tests such as HC2.  

In one of the authors’ own laboratories (RMA), three of 31 (10%) patients diagnosed with invasive cervical SCC and tested within the prior 12 months for hrHPV by HC2 from FDA-approved PreservCyt vial fluid had negative HC2 results. All three patients had HPV 18 detected by PCR in SCC sampled in paraffin sections, and two also had detectible HPV 16.  

HPV testing from the non-FDA-approved SurePath vial is thought to be more challenging, primarily due to the formaldehyde crosslinking of proteins and nucleic acids.  

Although recovery of DNA and ribonucleic acid is largely unaffected by long-term storage in PreservCyt, storage in SurePath preservative fluid (Becton Dickinson) has been shown to affect the recovery of both DNA and ribonucleic acid. Upon exposure to SurePath media, recovery of both DNA and ribonucleic acid rapidly diminished. This reduction was most apparent in the 0–150 hours range (ie, up to around 6 days). The websites of four large national laboratories that offer HC2 testing of referred SurePath samples all indicated that SurePath samples are stable at room temperature for HC2 testing for ≤1 month compared to 90 days/3 months for the FDA-approved ThinPrep® vial (Hologic) (Table 1). Interestingly, none of the laboratories, when queried by telephone, could produce independent SurePath–HC2 stability data; instead, laboratories referred to the FDA-approved Becton Dickinson package insert which states that SurePath preservative fluid preserves cells (for cytologic testing) for up to 4 weeks at room temperature (15°C–30°C). Even in the most widely cited “validation” study mentioned previously, the authors referred to the digene package insert for specimen stability parameters.  

Table 1 Testing times allowed for of samples collected for Hybrid Capture 2 human papillomavirus testing as indicated on national laboratory websites

<table>
<thead>
<tr>
<th>Laboratory</th>
<th>Digene® STM</th>
<th>ThinPrep®</th>
<th>SurePath™</th>
<th>Room temperature/refrigerated</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>14 days/21 days</td>
<td>3 months/6 months</td>
<td>1 month/6 months</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>21 days/21 days/90 days</td>
<td>3 months/28 days/90 days</td>
<td>21 days/28 days</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Not listed/unstable</td>
<td>28 days/unstable</td>
<td>28 days/30 days/30 days</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>14 days/21 days</td>
<td>90 days/90 days</td>
<td>30 days/30 days</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviation:** STM, specimen transport medium.
reported that HPV 16-positive control samples shipped in SurePath fluid degraded so rapidly that detectible HPV DNA was lost after 1 day.30 The vendor concluded that only use of a two tube methodology, separating the HPV 16 sample from the SurePath sample until the time of testing, could be used for laboratory HPV proficiency testing.31,32

There is at present no standardized SurePath HPV protocol that all laboratories use and no literature with sufficient detail to represent an agreed upon standard.6,7,33–36 Furthermore, the manufacturer cannot under current regulations recommend standardized procedures for non-FDA-approved hrHPV testing. As a result of continued ongoing widespread off-label HPV LDT use and related patient safety concerns, on June 8, 2012 the manufacturer of SurePath released a technical bulletin which stated:

“The Becton Dickinson SurePath sample medium has not been approved by the FDA for use with the HC2 test and use […] may under certain conditions provide false negative results. False negative results could lead to inappropriate patient management and potentially compromise patient safety.”

**Conclusion**

The authors echo the cautions of the new US screening guidelines that emphasize that extended screening intervals following negative hrHPV test results be based on HPV tests with performance characteristics similar to HPV tests used in the supporting evidence. Such supporting evidence is so far lacking for the hrHPV LDTs described here. Given those new cervical screening guidelines and manufacturer communications that caution against non-FDA-approved LDT hrHPV testing from the SurePath vial, it is reasonable to view continued widespread use of this nonstandardized off-label testing as a patient safety issue. With new, extended 5-year screening intervals proposed for many women, an increasing number of women will be screened every 5 years. An avoidable increase in false negative hrHPV results in women with both precancer and early invasive cervical cancer will place patients at unnecessary risk. The use of screening methods that have not been validated should be strongly discouraged.37,38 With four FDA-approved alternatives, it is difficult to justify the use of anything but rigorously clinically validated specimens. The College of American Pathologists should discontinue offering its current form of laboratory proficiency testing for HPV testing out of the SurePath vial, as it could mislead participants to believe that their methodology is currently safe and acceptable. For laboratories that use SurePath for cytology, co-collection of a second sample for hrHPV testing in an FDA-approved collection medium provides a safe and effective alternative.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


